See more : Renasant Corporation (RNST) Income Statement Analysis – Financial Results
Complete financial analysis of Adicet Bio, Inc. (ACET) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adicet Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Foresight Sustainable Forestry Company PLC (FSF.L) Income Statement Analysis – Financial Results
- Alwaha REIT Fund (9300.SR) Income Statement Analysis – Financial Results
- Braveheart Resources Inc. (BHT.V) Income Statement Analysis – Financial Results
- NCC Bluewater Products Limited (NCCBLUE.BO) Income Statement Analysis – Financial Results
- Idaho Strategic Resources, Inc. (IDR) Income Statement Analysis – Financial Results
Adicet Bio, Inc. (ACET)
About Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 24.99M | 9.73M | 17.90M | 995.00K | 8.18M | 558.52M | 546.95M | 510.18M | 499.69M | 499.69M | 444.39M | 412.43M | 346.63M | 322.65M | 359.59M |
| Cost of Revenue | 6.10M | 5.01M | 0.00 | 0.00 | 125.00K | 80.00K | 5.00K | 411.52M | 395.48M | 401.42M | 401.42M | 362.36M | 346.59M | 292.48M | 267.03M | 292.29M |
| Gross Profit | -6.10M | 19.98M | 9.73M | 17.90M | 870.00K | 8.10M | 558.52M | 135.43M | 114.70M | 98.27M | 98.27M | 82.03M | 65.84M | 54.16M | 55.62M | 67.31M |
| Gross Profit Ratio | 0.00% | 79.96% | 100.00% | 100.00% | 87.44% | 99.02% | 100.00% | 24.76% | 22.48% | 19.67% | 19.67% | 18.46% | 15.96% | 15.62% | 17.24% | 18.72% |
| Research & Development | 106.04M | 71.25M | 48.94M | 34.33M | 23.69M | 14.72M | 16.84M | 5.94M | 5.22M | 2.83M | 0.00 | 0.00 | 0.00 | 0.00 | 153.00K | 506.00K |
| General & Administrative | 26.53M | 26.30M | 22.22M | 22.76M | 8.69M | 8.43M | 76.82M | 73.16M | 65.21M | 61.02M | 63.86M | 56.67M | 49.29M | 44.72M | 43.57M | 45.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -74.78M | -73.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.53M | 26.30M | 22.22M | 22.76M | 8.69M | 8.43M | 2.04M | 1.00K | 65.21M | 61.02M | 63.86M | 56.67M | 49.29M | 44.72M | 43.57M | 45.42M |
| Other Expenses | 19.46M | -919.00K | -606.00K | -953.00K | 2.33M | 4.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 152.04M | 97.54M | 71.16M | 57.09M | 32.38M | 23.15M | 18.88M | 1.00K | 70.43M | 63.86M | 63.86M | 56.67M | 49.29M | 44.72M | 43.73M | 45.93M |
| Cost & Expenses | 152.04M | 97.54M | 71.16M | 57.09M | 32.38M | 23.15M | 18.88M | 1.00K | 465.91M | 465.27M | 465.27M | 419.02M | 395.88M | 337.19M | 310.75M | 338.21M |
| Interest Income | 9.95M | 3.76M | 91.00K | 785.00K | 938.00K | 543.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 80.00K | 176.00K | 134.00K | 0.00 | 0.00 | 7.00M | 3.95M | 2.10M | 2.12M | 2.12M | 2.63M | 1.57M | 230.00K | 98.00K | 145.00K |
| Depreciation & Amortization | 6.10M | 5.01M | 4.07M | 1.95M | 1.24M | 80.00K | 5.00K | 11.85M | 8.09M | 6.94M | 6.94M | 6.94M | 5.50M | 2.80M | 1.87M | 2.38M |
| EBITDA | -136.54M | -64.70M | -60.41M | -37.41M | -26.88M | -13.74M | -33.77M | -1.00K | 54.87M | 43.62M | 43.62M | 34.31M | 24.03M | 13.23M | 14.70M | 24.71M |
| EBITDA Ratio | 0.00% | -278.95% | -636.67% | -219.85% | -2,701.61% | -105.93% | -3.38% | 0.00% | 10.75% | 8.73% | 8.73% | 7.72% | 5.83% | 3.82% | 4.55% | 6.87% |
| Operating Income | -152.04M | -72.55M | -61.43M | -39.19M | -31.39M | -14.96M | -18.88M | -1.00K | 44.27M | 34.42M | 34.42M | 25.37M | 16.55M | 9.44M | 11.89M | 21.38M |
| Operating Income Ratio | 0.00% | -290.32% | -631.38% | -218.91% | -3,154.57% | -182.91% | -3.38% | 0.00% | 8.68% | 6.89% | 6.89% | 5.71% | 4.01% | 2.72% | 3.69% | 5.94% |
| Total Other Income/Expenses | 9.38M | 2.76M | -691.00K | -302.00K | 3.27M | 5.08M | -14.90M | 0.00 | 402.00K | 134.00K | 134.00K | -626.00K | 412.00K | 765.00K | 839.00K | 812.00K |
| Income Before Tax | -142.66M | -69.79M | -62.12M | -39.49M | -28.12M | -9.89M | -33.78M | -1.00K | 44.67M | 34.55M | 34.55M | 24.74M | 16.96M | 10.20M | 12.73M | 22.19M |
| Income Before Tax Ratio | 0.00% | -279.27% | -638.48% | -220.59% | -2,826.03% | -120.87% | -6.05% | 0.00% | 8.76% | 6.91% | 6.91% | 5.57% | 4.11% | 2.94% | 3.95% | 6.17% |
| Income Tax Expense | 0.00 | -2.76M | -125.00K | -2.82M | 19.00K | -589.00K | 19.09M | 20.38M | 15.67M | 12.22M | 12.22M | 7.76M | 7.99M | 3.62M | 4.10M | 8.72M |
| Net Income | -142.66M | -67.03M | -62.00M | -36.68M | -28.14M | -9.30M | -33.78M | -1.00K | 29.00M | 22.33M | 22.33M | 16.98M | 8.97M | 6.58M | 8.63M | 13.47M |
| Net Income Ratio | 0.00% | -268.22% | -637.19% | -204.87% | -2,827.94% | -113.67% | -6.05% | 0.00% | 5.68% | 4.47% | 4.47% | 3.82% | 2.17% | 1.90% | 2.67% | 3.75% |
| EPS | -3.31 | -1.63 | -2.00 | -5.01 | -1.52 | -0.31 | -1.26 | 0.00 | 1.18 | 0.94 | 0.94 | 0.73 | 0.40 | 0.30 | 0.40 | 0.63 |
| EPS Diluted | -3.31 | -1.63 | -2.00 | -5.01 | -1.52 | -0.31 | -1.25 | 0.00 | 1.16 | 0.93 | 0.93 | 0.72 | 0.39 | 0.30 | 0.39 | 0.62 |
| Weighted Avg Shares Out | 43.04M | 41.08M | 30.95M | 7.32M | 18.56M | 29.80M | 26.77M | 28.05M | 24.50M | 23.67M | 23.67M | 23.26M | 22.67M | 21.86M | 21.43M | 21.30M |
| Weighted Avg Shares Out (Dil) | 43.04M | 41.08M | 30.95M | 7.32M | 18.56M | 29.80M | 26.97M | 28.05M | 24.99M | 24.02M | 24.02M | 23.46M | 22.84M | 22.07M | 21.86M | 21.70M |
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 30, 2024. Three...
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering.
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has...
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally.
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted...
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on May 31, 2024. Two...
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will...
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter...
Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming...
Source: https://incomestatements.info
Category: Stock Reports